Literature DB >> 15228966

Effectiveness of the nicotine inhaler for smoking cessation in an OTC setting.

Scott J Leischow1, James Ranger-Moore, Myra L Muramoto, Eva Matthews.   

Abstract

OBJECTIVE: To evaluate the effectiveness of the Nicotrol nicotine inhaler as an aid to smoking cessation in over-the-counter (OTC) versus health-care-provider (HCP) conditions.
METHODS: Five hundred twenty healthy smokers were randomized to the treatment conditions and followed for a year.
RESULTS: At most follow-up visits, abstinence rates for the HCP group were 2 to 3 times those observed in the OTC group. Abstinence at 1 year was.77% in the OTC condition versus 3.08% in the HCP condition [P<.01]. Inhaler use was low.
CONCLUSIONS: OTC nicotine inhaler appears to be ineffective, though quit rates are improved with HCP assistance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228966     DOI: 10.5993/ajhb.28.4.1

Source DB:  PubMed          Journal:  Am J Health Behav        ISSN: 1087-3244


  13 in total

1.  Adherence to varenicline among African American smokers: an exploratory analysis comparing plasma concentration, pill count, and self-report.

Authors:  Taneisha S Buchanan; Carla J Berg; Lisa Sanderson Cox; Niaman Nazir; Neal L Benowitz; Lisa Yu; Olivia Yturralde; Peyton Jacob; Won S Choi; Jasjit S Ahluwalia; Nicole L Nollen
Journal:  Nicotine Tob Res       Date:  2012-02-24       Impact factor: 4.244

2.  A pilot clinical trial of varenicline for smoking cessation in black smokers.

Authors:  Nicole L Nollen; Lisa Sanderson Cox; Niaman Nazir; Edward F Ellerbeck; Ashli Owen; Sydni Pankey; Nia Thompson; Jasjit S Ahluwalia
Journal:  Nicotine Tob Res       Date:  2011-04-15       Impact factor: 4.244

Review 3.  Effectiveness of over-the-counter nicotine replacement therapy: a qualitative review of nonrandomized trials.

Authors:  John R Hughes; Erica N Peters; Shelly Naud
Journal:  Nicotine Tob Res       Date:  2011-04-06       Impact factor: 4.244

4.  Lessons learned in the development and evaluation of RxCoach™, an mHealth app to increase tobacco cessation medication adherence.

Authors:  Judith S Gordon; Julie S Armin; James K Cunningham; Myra L Muramoto; Steven M Christiansen; Thomas A Jacobs
Journal:  Patient Educ Couns       Date:  2016-11-08

5.  Relationships of PROP Taste Phenotype, Taste Receptor Genotype, and Oral Nicotine Replacement Use.

Authors:  Karen Ahijevych; Beverly J Tepper; Margaret C Graham; Christopher Holloman; William A Matcham
Journal:  Nicotine Tob Res       Date:  2014-12-26       Impact factor: 4.244

6.  A text message delivered smoking cessation intervention: Design and rationale of the Text My Quit Study.

Authors:  Christopher Deutsch; Beth C Bock; Ryan Lantini; Kristen Walaska; Rochelle K Rosen; Joseph L Fava; Ernestine G Jennings; Robert Foster; William Flanagan
Journal:  Contemp Clin Trials       Date:  2019-04-15       Impact factor: 2.226

7.  Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.

Authors:  Nicola Lindson; Samantha C Chepkin; Weiyu Ye; Thomas R Fanshawe; Chris Bullen; Jamie Hartmann-Boyce
Journal:  Cochrane Database Syst Rev       Date:  2019-04-18

Review 8.  Interventions for preventing weight gain after smoking cessation.

Authors:  Jamie Hartmann-Boyce; Annika Theodoulou; Amanda Farley; Peter Hajek; Deborah Lycett; Laura L Jones; Laura Kudlek; Laura Heath; Anisa Hajizadeh; Marika Schenkels; Paul Aveyard
Journal:  Cochrane Database Syst Rev       Date:  2021-10-06

Review 9.  Research priorities for Article 14--demand reduction measures concerning tobacco dependence and cessation.

Authors:  Hayden McRobbie; Martin Raw; Sophia Chan
Journal:  Nicotine Tob Res       Date:  2012-11-08       Impact factor: 4.244

10.  Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial.

Authors:  Nia Thompson; Niaman Nazir; Lisa Sanderson Cox; Babalola Faseru; Kathy Goggin; Jasjit S Ahluwalia; Nicole L Nollen
Journal:  Patient Prefer Adherence       Date:  2011-09-28       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.